Results 21 to 30 of about 1,978 (184)

Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027) [PDF]

BMC Public Health
Background/aims The dapivirine vaginal ring is a self-administered, women-initiated, discreet, long-acting HIV-1 prevention option for women. It was found to be safe and effective in healthy HIV-negative women who adhered to product use instructions, and
Cecilia Milford, Hariska Ramlal, Rorisang Mofokeng, Letitia Rambally Greener, Annaléne Nel, Jennifer Smit, Mariëtte Malherbe   +6 more
doaj   +2 more sources

PrEP and choice counselling – Insights into implementation [PDF]

Journal of Public Health in Africa
Adolescent girls and young women are disproportionately affected by human immunodeficiency virus (HIV). The introduction of oral pre-exposure prophylaxis (PrEP) was a game-changer in HIV prevention.
Melanie Pleaner, Faith Musvipwa, Siphokazi Dada, Fatima A. Cholo, Catherine E. Martin, Alison Kutywayo, Vusile Butler, Saiqa Mullick   +7 more
doaj   +2 more sources

Density Mediated Drug Release From Dapivirine Vaginal Rings Produced by Additive Manufacturing [PDF]

, 2018
Background: Droplet deposition modelling (DDM) is a form of 3D printing that fuses droplets of molten polymer to create each layer, providing exquisite levels of control over an object‘s design and morphology.
Boyd, Peter, Devlin, Brid, Malcolm, Robert, McCoy, Clare F., Murphy, Diarmaid, Welsh, Nicole   +5 more
core   +3 more sources

Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status. [PDF]

Infez Med
Latin America has reported a 9% increase in new HIV infections from 2010 to 2023. Pre-exposure prophylaxis (PrEP) is a crucial biomedical intervention for preventing HIV transmission.
Gonzales-Gavancho C, Araoz-Salinas JM, Ramon Tapia R, Quispe-Vicuña C, Reategui-Garcia ME, Rios-Garcia W, Baltodano-Calle MJ, Belanovic-Ramirez I, Ortiz-Pardo AN, Ortiz-Saavedra B, Campos VYM, Alave J, Gonzales-Zamora JA.   +12 more
europepmc   +3 more sources

Leveraging international stakeholders’ experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study [PDF]

Health Research Policy and Systems
Background Costing and financing systematic implementation are recognized barriers to human immunodeficiency virus (HIV) prevention. In the absence of empiric implementation and economic data, perspectives from international stakeholders involved in ...
Craig J. Heck, Katharine Kripke, Anita Dam, Sergio Torres-Rueda, Fiammetta Bozzani, Chris Obermeyer, Kibret Yohannes, Justine Deacon, Kathrine Meyers, Daniela Quigee, Sarah Wiant, Steven Forsythe, Christine Malati, Martha Larson, Magdalena E. Sobieszczyk, Delivette Castor   +15 more
doaj   +2 more sources

Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction. [PDF]

Clin Infect Dis, 2023
Steytler J, Craig C, van der Ryst E, Van Baelen B, Nuttall J, van Niekerk N, Mellors J, Parikh U, Wallis C, Ring Study and the DREAM Trial Study Teams.   +9 more
europepmc   +2 more sources

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial. [PDF]

J Int AIDS Soc, 2021
AbstractIntroductionA potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug‐resistant virus that could spread and reduce the effectiveness of non‐nucleoside reverse transcriptase (NNRTI)‐based first‐line antiretroviral therapy.
Parikh UM, Penrose KJ, Heaps AL, Halvas EK, Goetz BJ, Gordon KC, Hardesty R, Sethi R, Schwarzmann W, Szydlo DW, Husnik MJ, Chandran U, Palanee-Phillips T, Baeten JM, Mellors JW, MTN-020 Study Team.   +15 more
europepmc   +4 more sources

Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations. [PDF]

Br J Clin Pharmacol, 2018
AimsA physiologically‐based pharmacokinetic (PBPK) model of the vaginal space was developed with the aim of predicting concentrations in the vaginal and cervical space. These predictions can be used to optimize the probability of success of vaginally administered dapivirine (DPV) for HIV prevention.
Kay K, Shah DK, Rohan L, Bies R.
europepmc   +4 more sources

HIV-1 testing in the context of expanding PrEP modalities. [PDF]

J Int AIDS Soc
Abstract Introduction Multiple effective antiretroviral‐based pre‐exposure prophylaxis (PrEP) modalities for HIV‐1 prevention are now available or under investigation but their safe rollout requires implementable HIV‐1 testing strategies that accurately identify rare cases of HIV‐1 acquisition.
Parikh UM, Jacobs JL, Njuguna N, Torjesen K, Mellors JW.   +4 more
europepmc   +2 more sources

In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel

International Journal of Pharmaceutics: X, 2022
We have previously reported a multipurpose silicone elastomer vaginal ring providing sustained release of dapivirine (an antiretroviral) and levonorgestrel (a progestin) for HIV prevention and hormonal contraception.
Diarmaid J. Murphy, Yahya H. Dallal Bashi, Clare F. McCoy, Peter Boyd, Leeanne Brown, François Martin, Nicole McMullen, Kyle Kleinbeck, Bindi Dangi, Patrick Spence, Bashir Hansraj, Bríd Devlin, R. Karl Malcolm   +12 more
doaj   +1 more source